Uncategorized Archives - Page 13 of 248

WednesdayJan 17, 2024 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Set to Expedite Human and Animal Studies on DehydraTECH’s Effectiveness on GLP-1 Drugs Following Positive Results from Pilot Study

Lexaria, a global specialist in drug delivery platforms, just announced the final results from its recently completed human Pilot Study #1 on the effectiveness of its patented DehydraTECH(TM) technology on the oral delivery of GLP-1 drug, semaglutide The results showed improved delivery of semaglutide to the bloodstream, with the drug showing approximately 44% higher levels than the control 24 hours after ingestion of a single dose DehydraTECH GLP-1 processed semaglutide also proved to be better tolerated than the control, with the latter resulting in some cases of moderate nausea and diarrhea This milestone brings Lexaria closer to tapping into the…

MondayJan 08, 2024 11:15 am

Astrotech Corp. (NASDAQ: ASTC) Announces New Mass Spectrometry Technology Application for Chemical Manufacturing and Introduces the Pro-Control Subsidiary

Astrotech’s newest subsidiary, Pro-Control, will use the company’s mass spectrometer technology to improve purity, and yields of distilled chemicals Pro-Control delivers value by improving lost yields and delivering found profits directly to the bottom line with little, which the company believes will lead to an overall increase in profitability Astrotech believes that the Pro-Control MVP has the ability to routinely improve yields from 20% to 30% The company is introducing its proprietary ATi Mass Spectrometer Technology into the vast chemical manufacturing and process control markets Astrotech (NASDAQ: ASTC), is an instrumentation company that is focused on commercializing its proprietary ATi…

ThursdayDec 28, 2023 4:20 pm

420 with CNW — Ohio Marijuana Sector in Limbo as Lawmakers Close for the Year

Last week marked the conclusion of the Ohio Senate and House’s final scheduled sessions for the year, yet the anticipated progress on cannabis legislation remained elusive. Despite both chambers convening on Wednesday, no cannabis-related bills were discussed, prompting questions about the proximity of a consensus between the Senate and House on the matter. Senate president Matt Huffman expressed uncertainty about the progress, noting that it was “challenging to determine. The provisions we endorsed, developed in collaboration with the governor and presented to the House have not received significant feedback.” In a bipartisan move, the Senate passed HB 86, advocating for…

WednesdayDec 27, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Provides Superior Drug and API Delivery with Patented DehydraTECH Technology

Lexaria, a global innovator in drug delivery platforms, has made incredible strides in 2023, most recently seeing interim results from its human pilot study evaluating its DehydraTECH(TM) technology for the oral delivery of GLP-1 drug, semaglutide The company has also grown its patent portfolio to 37, with many others pending worldwide For 2024, the company expects to maintain the same momentum, building on the success and achievements, and plans to double down on licensing its technology Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, in this past year, has demonstrated growing success in providing healthier delivery methods…

ThursdayDec 21, 2023 4:20 pm

420 with CNW — Pilot Project for Marijuana Legalization Starts in Netherlands

For years, Dutch coffee shops have functioned in a system where cannabis sale was permitted, but its growth remained illegal. This led to a lack of transparency for consumers, leaving them unaware of the origins, growers and conditions under which the products they purchased were cultivated. However, that will soon change as the government initiates a marijuana legalization pilot project. The initial phase of a closed-chain experiment, designed to deliver marijuana from legally sanctioned cultivation to coffee shops commenced on Dec. 15, 2023. The current timeline indicates that two authorized producers will be prepared to supply coffee shops in the…

ThursdayDec 21, 2023 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) To File its IND Application with the FDA for its planned U.S. Phase 1b Hypertension Clinical Trial

Lexaria, a global innovator in drug delivery platforms, expects to submit its IND application for its planned U.S. Phase 1b Hypertension Clinical Trial with the FDA within the next 45 days The HYPER-H23-1 clinical study will build on five successful human clinical trials conducted so far, studying the company’s patented DehydraTECH(TM)-processed CBD in an aggregate total of 134 individuals Lexaria’s patented DehydraTECH(TM) “drug delivery platform technology” increases bioavailability, improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced that it anticipates submitting its Investigational New Drug (“IND”)…

ThursdayDec 21, 2023 8:54 am

HEMP BioSciences Inc. a Wholly-owned Division of WEED Inc. Receives Full Suite of Industrial Hemp Licenses From State of Arizona

WEED Inc. subsidiary will begin buildout of its cGMP certified kitchen to begin manufacturing of consumer-packaged goods TUCSON, Ariz., Dec. 21, 2023 (GLOBE NEWSWIRE) — via IBN – WEED Inc. (OTCQB: BUDZ), (“WEED,” “HEMP” or the “Company”), a global cannabis and hemp bioresearch company based in the U.S. focused on the development and application of cannabis–derived compounds for the treatment of human and animal diseases, announces today that it intends to expand into consumer packaged goods utilizing the Company’s rare Landrace strains including Original Panama Red, Acapulco Gold, Red Bud Colombian and Santa Marta Gold. WEED Inc aims to shape…

WednesdayDec 13, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes Additional Revenue Opportunities for 2024; Continues to Generate New Data for its DehydraTECH Technology

Lexaria, a global innovator in drug delivery platforms, is projected by Zacks SCR to be valued at $10 a share, up from the current $1.50 for 2024 Zacks SCR projects a 259% YOY revenue growth for 2024 and a 20% growth for 2025, dependent upon the ultimate approval and commercialization of products employing its patented DehydraTECH(TM) technology Lexaria also anticipates FDA approval for its IND application and commence its Phase 1b hypertension clinical trial, all in 2024 Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has had significant developments in 2023. Most notably, the company has seen…

MondayDec 11, 2023 9:00 am

Astrotech Corp. (NASDAQ: ASTC) Is ‘One to Watch’

In November 2023, the company announced a purchase order from a Romanian company for seven TRACER 1000 ETDs to be deployed in a European airport Astrotech announced in June 2023 that its board unanimously rejected an unsolicited acquisition proposal from BML Investment Partners In May 2023, the company announced a purchase order from a Romanian company for 17 TRACER 1000 ETDs, to be delivered during calendar 2023 Astrotech confirmed test results from field trials of the AgLAB 1000-D2 mass spectrometer for hemp and cannabis producers, improving yields by an average of 24% In December 2022, the company effected a 1-for-30…

TuesdayDec 05, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Interim Results in Ongoing GLP-1 Human Pilot Study

Lexaria, a global innovator in drug delivery platforms, just announced additional positive interim results from its ongoing GLP-1 human pilot study The study seeks to provide an early-stage indication of whether DehydraTECH(TM) processing could improve oral drug delivery characteristics of the GLP-1 drug semaglutide Lexaria’s DehydraTECH GLP-1 showed a 2.9% to 14.6% blood glucose level reduction relative to baseline, compared to 1.3% to 6.7% for the control group The DehydraTECH GLP-1 group also only saw a 5.3% spike in glucose levels after having a standardized meal at the 240-minute mark and a snack at the 360-minute mark, compared to 22.7%…